Sutro Biopharma Beats Q1 EPS Estimates, Extends Cash Runway to Q2 2028, and Reports Pipeline Progress
STRO has more than doubled off its 52-week low of $6.736.
Summary
Sutro Biopharma reported better-than-expected Q1 2026 financial results, significantly reducing its net loss and extending its cash runway to Q2 2028, while also highlighting key pipeline advancements.
Key Events · Earnings and Guidance · STRO
-
Q1 2026 Financial Results Beat Estimates
The company reported a net loss per share of $(2.94) for Q1 2026, significantly better than the analyst consensus estimate of $(3.77). Net loss improved to $(38.484) million from $(75.968) million in Q1 2025.
-
Cash Runway Extended to Q2 2028
Sutro Biopharma reported $202.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Including gross proceeds from a $110 million underwritten offering (completed in February 2026), the company's cash runway is now expected to last into at least the second quarter of 2028.
-
Pipeline Progress and Milestone Payment
The Phase 1 dose-escalation trial for STRO-004 is progressing, with initial safety, PK, and early activity data expected in mid-2026. IND submissions for STRO-006 and STRO-227 are planned for 2026. Additionally, a $10 million milestone payment was received in April 2026 as the first dual-payload iADC under the Astellas collaboration entered the clinic.
-
Reduced Operating Expenses
Total R&D and G&A expenses for Q1 2026 decreased to $44.1 million, compared to $64.9 million for Q1 2025, indicating improved cost management.
Analysis · STRO · Life Sciences
Sutro Biopharma reported first-quarter 2026 financial results that significantly beat analyst expectations for EPS, alongside a substantial reduction in net loss. The company also announced a strengthened balance sheet, with cash and equivalents of $202.6 million, which, combined with proceeds from a recent $110 million underwritten offering, extends its cash runway into at least the second quarter of 2028. This financial stability is critical for a clinical-stage biotech, de-risking operations and supporting ongoing pipeline advancements, including upcoming data readouts for STRO-004 and planned IND submissions for STRO-006 and STRO-227.
At the time of this filing, STRO was trading at $38.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $636.5M. The 52-week trading range was $6.74 to $41.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.